Literature DB >> 20850858

HIV-1 Gag p17 presented as virus-like particles on the E2 scaffold from Geobacillus stearothermophilus induces sustained humoral and cellular immune responses in the absence of IFNγ production by CD4+ T cells.

Antonella Caivano1, Nicole A Doria-Rose, Benjamin Buelow, Rossella Sartorius, Maria Trovato, Luciana D'Apice, Gonzalo J Domingo, William F Sutton, Nancy L Haigwood, Piergiuseppe De Berardinis.   

Abstract

We have constructed stable virus-like particles displaying the HIV-1 Gag(p17) protein as an N-terminal fusion with an engineered protein domain from the Geobacillus stearothermophilus pyruvate dehydrogenase subunit E2. Mice immunized with the Gag(p17)-E2 60-mer scaffold particles mounted a strong and sustained antibody response. Antibodies directed to Gag(p17) were boosted significantly with additional immunizations, while anti-E2 responses reached a plateau. The isotype of the induced antibodies was biased towards IgG1, and the E2-primed CD4+ T cells did not secrete IFNγ. Using transgenic mouse model systems, we demonstrated that CD8+ T cells primed with E2 particles were able to exert lytic activity and produce IFNγ. These results show that the E2 scaffold represents a powerful vaccine delivery system for whole antigenic proteins or polyepitope engineered proteins, evoking antibody production and antigen specific CTL activity even in the absence of IFNγ-producing CD4+ T cells.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20850858      PMCID: PMC3275809          DOI: 10.1016/j.virol.2010.08.026

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  53 in total

Review 1.  New recombinant vaccines based on the use of prokaryotic antigen-display systems.

Authors:  Piergiuseppe De Berardinis; Nancy L Haigwood
Journal:  Expert Rev Vaccines       Date:  2004-12       Impact factor: 5.217

2.  Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates.

Authors:  Sampa Santra; Michael S Seaman; Ling Xu; Dan H Barouch; Carol I Lord; Michelle A Lifton; Darci A Gorgone; Kristin R Beaudry; Krisha Svehla; Brent Welcher; Bimal K Chakrabarti; Yue Huang; Zhi-Yong Yang; John R Mascola; Gary J Nabel; Norman L Letvin
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

3.  Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit.

Authors:  S W Barnett; S Rajasekar; H Legg; B Doe; D H Fuller; J R Haynes; C M Walker; K S Steimer
Journal:  Vaccine       Date:  1997-06       Impact factor: 3.641

4.  The catalytic domain of dihydrolipoyl acetyltransferase from the pyruvate dehydrogenase multienzyme complex of Bacillus stearothermophilus. Expression, purification and reversible denaturation.

Authors:  M D Allen; R N Perham
Journal:  FEBS Lett       Date:  1997-08-18       Impact factor: 4.124

5.  Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

Authors:  R Shibata; T Igarashi; N Haigwood; A Buckler-White; R Ogert; W Ross; R Willey; M W Cho; M A Martin
Journal:  Nat Med       Date:  1999-02       Impact factor: 53.440

6.  Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus.

Authors:  L O Arthur; J W Bess; R G Urban; J L Strominger; W R Morton; D L Mann; L E Henderson; R E Benveniste
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

Review 7.  The regulation of immunity to Leishmania major.

Authors:  S L Reiner; R M Locksley
Journal:  Annu Rev Immunol       Date:  1995       Impact factor: 28.527

8.  Expression of genes encoding the E2 and E3 components of the Bacillus stearothermophilus pyruvate dehydrogenase complex and the stoichiometry of subunit interaction in assembly in vitro.

Authors:  I A Lessard; G J Domingo; A Borges; R N Perham
Journal:  Eur J Biochem       Date:  1998-12-01

9.  Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine.

Authors:  L O Arthur; J W Bess; E N Chertova; J L Rossio; M T Esser; R E Benveniste; L E Henderson; J D Lifson
Journal:  AIDS Res Hum Retroviruses       Date:  1998-10       Impact factor: 2.205

10.  HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice.

Authors:  S Pascolo; N Bervas; J M Ure; A G Smith; F A Lemonnier; B Pérarnau
Journal:  J Exp Med       Date:  1997-06-16       Impact factor: 14.307

View more
  15 in total

1.  Novel antigen delivery systems.

Authors:  Maria Trovato; Piergiuseppe De Berardinis
Journal:  World J Virol       Date:  2015-08-12

2.  Delivery strategies for novel vaccine formulations.

Authors:  Maria Trovato; Shelly J Krebs; Nancy L Haigwood; Piergiuseppe De Berardinis
Journal:  World J Virol       Date:  2012-02-12

3.  Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates.

Authors:  Sean P McBurney; Justine E Sunshine; Sarah Gabriel; Jeremy P Huynh; William F Sutton; Deborah H Fuller; Nancy L Haigwood; William B Messer
Journal:  Vaccine       Date:  2016-04-13       Impact factor: 3.641

4.  Complement activation and cell uptake responses toward polymer-functionalized protein nanocapsules.

Authors:  Nicholas M Molino; Kateryna Bilotkach; Deborah A Fraser; Dongmei Ren; Szu-Wen Wang
Journal:  Biomacromolecules       Date:  2012-03-14       Impact factor: 6.988

5.  Biomimetic protein nanoparticles facilitate enhanced dendritic cell activation and cross-presentation.

Authors:  Nicholas M Molino; Amanda K L Anderson; Edward L Nelson; Szu-Wen Wang
Journal:  ACS Nano       Date:  2013-10-09       Impact factor: 15.881

Review 6.  Advancements in protein nanoparticle vaccine platforms to combat infectious disease.

Authors:  Nina Butkovich; Enya Li; Aaron Ramirez; Amanda M Burkhardt; Szu-Wen Wang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2020-11-08

7.  Co-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cells.

Authors:  Juan Pablo Jaworski; Shelly J Krebs; Maria Trovato; Dina N Kovarik; Zachary Brower; William F Sutton; Garrett Waagmeester; Rossella Sartorius; Luciana D'Apice; Antonella Caivano; Nicole A Doria-Rose; Delphine Malherbe; David C Montefiori; Susan Barnett; Piergiuseppe De Berardinis; Nancy L Haigwood
Journal:  PLoS One       Date:  2012-02-16       Impact factor: 3.240

8.  Multimeric scaffolds displaying the HIV-1 envelope MPER induce MPER-specific antibodies and cross-neutralizing antibodies when co-immunized with gp160 DNA.

Authors:  Shelly J Krebs; Sean P McBurney; Dina N Kovarik; Chelsea D Waddell; J Pablo Jaworski; William F Sutton; Michelle M Gomes; Maria Trovato; Garret Waagmeester; Susan J Barnett; Piergiuseppe DeBerardinis; Nancy L Haigwood
Journal:  PLoS One       Date:  2014-12-16       Impact factor: 3.240

9.  Distinct Antigen Delivery Systems Induce Dendritic Cells' Divergent Transcriptional Response: New Insights from a Comparative and Reproducible Computational Analysis.

Authors:  Valerio Costa; Dario Righelli; Francesco Russo; Piergiuseppe De Berardinis; Claudia Angelini; Luciana D'Apice
Journal:  Int J Mol Sci       Date:  2017-02-25       Impact factor: 5.923

10.  E2 multimeric scaffold for vaccine formulation: immune response by intranasal delivery and transcriptome profile of E2-pulsed dendritic cells.

Authors:  Maria Trovato; Francesco Maurano; Luciana D'Apice; Valerio Costa; Rossella Sartorius; Fausta Cuccaro; Sean P McBurney; Shelly J Krebs; Antonella Prisco; Alfredo Ciccodicola; Mauro Rossi; Nancy L Haigwood; Piergiuseppe De Berardinis
Journal:  BMC Microbiol       Date:  2016-07-16       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.